Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue: +1,188.7%
EPS: −18.0%
Free cash flow: −99.1%
Total debt: +322.7%

Quarter to September 2026, against a year earlier

193.33 15.68 +8.83%

Follow RVMD

Alert me

Market cap: $38.1B
P/E: 0.0×
Fwd P/E: −11.9×
Dividend yield: —
F-score: 4/9
Altman Z: 7.73
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Revolution Medicines, Inc. (RVMD) revenue by segment, product and region

	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020
Collaboration Revenue Member	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration Revenue Related Party	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Collaboration Revenues Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Revolution Medicines, Inc. (RVMD) revenue by segment, product and region

Stockrow Weekly